Annual report [Section 13 and 15(d), not S-K Item 405]

OPERATING SEGMENT

v3.25.0.1
OPERATING SEGMENT
12 Months Ended
Dec. 31, 2024
OPERATING SEGMENT  
OPERATING SEGMENT

13. OPERATING SEGMENT

The Company has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer. The accounting policies of the single operating segment are the same as those of the Company. The chief operating decision maker is the Company’s president and CEO, who manages the Company’s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated operating expenses, which are reported in the consolidated statements of operations. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. Expenditures for additions to long-lived assets, which include purchases of property and equipment, are included in total consolidated assets reviewed by management and are reported on the consolidated statements of cash flows.

Management uses consolidated cash used in operations and budget-to-actual variances for consolidated net loss to assess the performance of the operating segment and evaluate performance and to allocate resources.

The following table presents certain financial data for the Company’s one reportable segment:

    

Year Ended December 31,

    

2024

    

2023

Research and development:

 

  

 

  

Phase 2 study in WM

$

7,422,000

$

12,652,000

Phase 1 study in pediatric tumors

 

3,040,000

 

2,480,000

Manufacturing and related costs

 

10,582,000

 

9,341,000

Pre-clinical projects costs

 

228,000

 

483,000

General research and development costs

 

4,864,000

 

2,310,000

General and administrative

 

25,641,000

 

11,694,000

Other segment items

 

(7,196,000)

 

3,811,000

Segment and consolidated net loss

$

44,581,000

$

42,771,000

Other segment items consist of warrant issuance expense, (gain) loss on valuation of warrants, and interest income.